Mavorixafor
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
WHIM syndrome: from mechanism to targeted therapy - advances shaping clinical care.
Journal: Current opinion in allergy and clinical immunology
Published: December 26, 2025
Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.
Journal: Current therapeutic research, clinical and experimental
Published: August 07, 2025
CXCR4 antagonism corrects neutrophil abnormalities and reduces pneumonia severity in a pharmacological mouse model of CXCR2 loss-of-function-mediated neutropenia.
Journal: Frontiers in immunology
Published: July 03, 2025
Mavorixafor: a CXCR4 antagonist for WHIM syndrome.
Journal: Immunopharmacology and immunotoxicology
Published: April 14, 2025
Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 10, 2025
Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024.
Journal: Expert opinion on therapeutic patents
Published: February 10, 2025
Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.
Journal: Clinical and experimental immunology
Published: October 18, 2024
Mavorixafor.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: July 30, 2024
CXCR4 antagonism ameliorates leukocyte abnormalities in a preclinical model of WHIM syndrome.
Journal: Frontiers in immunology
Published: July 22, 2024
Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024.
Journal: Annals of medicine and surgery (2012)
Published: July 04, 2024
Last Updated: 02/24/2026